Drug Trial Radar · NCT02631551
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,180
Actual
Start
Mar 2016
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- Glenmark Specialty S.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the efficacy and safety of GSP 301 NS compared to placebo NS and to individual monotherapies (comparators) as well as the efficacy of these monotherapies (comparators) versus placebo NS over 14 days of study treatment
Conditions
- Seasonal Allergic Rhinitis
Interventions
GSP 301 NSDrug
FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
Olopatadine HCl NSDrug
2 sprays in each nostril twice daily for 14 days
Mometasone furoate NSDrug
2 sprays in each nostril twice daily for 14 days
GSP 301 Placebo NSDrug
2 sprays in each nostril twice daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment.Time frame: 14 days
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site 20
Mission Viejo, California
Investigational Site 31
San Diego, California
Investigational Site 29
San Jose, California
Investigational Site 25
Centennial, Colorado
Investigational Site 22
Colorado Springs, Colorado
Investigational Site 10
Jupiter, Florida
Investigational Site 30
Miami, Florida
Investigational Site 37
Marietta, Georgia
Investigational Site 15
Stockbridge, Georgia
Investigational Site 23
Stockbridge, Georgia
Investigational Site 11
Louisville, Kentucky
Investigational Site 14
Baltimore, Maryland
Investigational Site 33
Wheaton, Maryland
Investigational Site 26
Ypsilanti, Michigan
Investigational Site 19
Minneapolis, Minnesota
Investigational Site 21
St Louis, Missouri
Investigational Site 16
Bellevue, Nebraska
Investigational Site 12
Skillman, New Jersey
Investigational Site 36
Rochester, New York
Investigational Site 18
Raleigh, North Carolina
Investigational Site 27
Cincinnati, Ohio
Investigational Site 34
Middleburg Heights, Ohio
Investigational Site 32
Medford, Oregon
Investigational Site 35
Portland, Oregon
Investigational Site 13
Orangeburg, South Carolina
Investigational Site 17
Spartanburg, South Carolina
Investigational Site 3
Austin, Texas
Investigational Site 5
Austin, Texas
Investigational Site 8
Austin, Texas
Investigational Site 1
Kerrville, Texas
Investigational Site 7
New Braunfels, Texas
Investigational Site 2
San Antonio, Texas
Investigational Site 4
San Antonio, Texas
Investigational Site 6
San Antonio, Texas
Investigational Site 9
San Antonio, Texas
Investigational Site 28
Waco, Texas
Investigational Site 24
Draper, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.